% | $
Quotes you view appear here for quick access.

ONYX Pharmaceuticals, AŞ Message Board

  • johnpapas893 johnpapas893 Oct 26, 2012 8:00 PM Flag

    Daily Trade Flow Review for Onyx Pharmaceuticals

    Could it be that this type of complete nonsense has been pushing the price lower?

    Daily Trade Flow Review for Onyx Pharmaceuticals
    Posted on 10/26/2012 by Allen Bersch
    NEW YORK (AVAFIN) -- A record number of Onyx Pharmaceuticals call contracts were traded during the busy trading session. There were 1.3 call contracts traded for each put contract yielding a 0.79 put/call ratio where 4,680 put and 5,960 call contracts exchanged hands.

    The skewed options ratio suggests that traders are re-balancing their portfolios in anticipation of a price shift. Unusual volume activity directly reflects investor outlook and confirms that a stock move is imminent.

    With its minimal in-house R&D capabilities, Onyx could be left empty-handed if competitors demonstrate superior efficacy to Nexavar or Kyprolis fails to penetrate the global market. Additionaly, Nexavar yielded disappointing Phase III trial results in both lung cancer and metastatic melanoma, raising doubt about its ability to treat a wide array of cancers.

    ONXX is trading below the 50 day moving average and higher than the 200 day moving average. Onyx Pharmaceuticals opened at $81.97 and the stock price declined $2.09 (2.55%) to $79.89 during the market session. ONXX is trading between the range of $78.01 - $82.47. Performance indicators show that the stock has lost -0.65% within the last month.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies